Home » Stocks » TAK

Takeda Pharmaceutical Company Limited (TAK)

Stock Price: $16.87 USD 0.25 (1.50%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 53.47B
Revenue (ttm) 30.50B
Net Income (ttm) 410.02M
Shares Out 3.15B
EPS (ttm) 0.53
PE Ratio 32.10
Forward PE 9.75
Dividend $180.00
Dividend Yield 1,066.98%
Trading Day May 7
Last Price $16.87
Previous Close $16.62
Change ($) 0.25
Change (%) 1.50%
Day's Open 16.80
Day's Range 16.75 - 16.99
Day's Volume 2,418,011
52-Week Range 15.30 - 19.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Takeda Pharmaceutical (TAK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

5 days ago - Zacks Investment Research

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE)...

1 week ago - Business Wire

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priori...

1 week ago - Business Wire

You might want to consider adding this company to your portfolio.

Other stocks mentioned: ARKG, JNJ, MRK, MRNA, NVAX, PFE
2 weeks ago - The Motley Fool

With the trading day about halfway over, the broad markets were pulling back after setting record highs to close out last week.

Other stocks mentioned: COUR, QCOM, CADE, DFS, EVRG, LSCC, TCOM
2 weeks ago - 24/7 Wall Street

Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into Longview Acquisition Corp. II (NYSE:LGV.U) according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: BHC, CI, DXC, THC
1 month ago - GuruFocus

The company is taking back rights to one drug candidate and discontinuing development of another.

Other stocks mentioned: MTEM
1 month ago - The Motley Fool

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide upd...

1 month ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to O...

1 month ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Comp...

1 month ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has teamed up with BridGene Biosciences to discover small molecules against hard-to-drug therapeutic targets. The deal will utilize BridGene's IMTAC Chemoproteom...

1 month ago - Benzinga

Cathie Wood's Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain s...

Other stocks mentioned: AMZN, BABA, GOOG, GOOGL, PLTR
1 month ago - Benzinga

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company's...

1 month ago - Business Wire

Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd (NYSE: TAK), covering as many as six programs for genetically-defined neur...

1 month ago - Benzinga

Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into HighCape Capital Acquisition Corp. (NASDAQ:CAPA) according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: BHC, CAPA, CI, DXC, THC
1 month ago - GuruFocus

Japan's Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's (NYSE: JNJ) single-dose COVID-19 vaccine....

1 month ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood a...

1 month ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufac...

1 month ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks

1 month ago - Business Wire

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Gr...

1 month ago - Business Wire

DEPTFORD, N.J.--(BUSINESS WIRE)--BioLife Plasma Services announces the opening of its first plasma donation center in New Jersey.

1 month ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right...

Other stocks mentioned: TXAC
1 month ago - Benzinga

OSAKA, Japan & BRISBANE, Calif.--(BUSINESS WIRE)--Takeda exercised its option to acquire Maverick, expanding its immuno-oncology portfolio with two development candidates and a T-cell engager platform

1 month ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has asked regulators to approve the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (mRNA-1273 or TAK-919). Takeda filed the New Drug Application to import ...

Other stocks mentioned: MRNA
2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces New Drug Application submitted to import and distribute Moderna's COVID-19 vaccine candidate in Japan.

Other stocks mentioned: MRNA
2 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic en...

Other stocks mentioned: OVID
2 months ago - Benzinga

OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.

Other stocks mentioned: OVID
2 months ago - Business Wire

Neurocrine Biosciences Inc (NASDAQ: NBIX) announces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment...

Other stocks mentioned: NBIX
2 months ago - Benzinga

SOFIA, Bulgaria--(BUSINESS WIRE)-- #Bulgaria--Takeda been officially recognized as one of the best places to work in Bulgaria for 2021 according to the annual prestigious “Best Places To Work” certifica...

2 months ago - Business Wire

Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Other stocks mentioned: ANTM, BHC, DD, NSC, THC
2 months ago - GuruFocus

Takeda Pharmaceutical Co Ltd (NYSE: TAK) will sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1.25 billio...

2 months ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to transfer the assets, marketing rights and...

2 months ago - Business Wire

MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.

2 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical trial. The fir...

Other stocks mentioned: NVAX
2 months ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax' COV...

2 months ago - Business Wire

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

2 months ago - Zacks Investment Research

ZURICH--(BUSINESS WIRE)-- #EURORDISAwards2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement...

2 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has announced data from SOLSTICE Phase 3 trial, evaluating maribavir (TAK-620) in hematopoietic cell transplant and solid organ transplant recipients with cytome...

2 months ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint

2 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with non-active/...

2 months ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and We...

2 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 3...

3 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

3 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch ...

3 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold...

3 months ago - Business Wire

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally ...

3 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This a...

3 months ago - Business Wire

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) In...

3 months ago - Business Wire

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT ...
3 months ago - Seeking Alpha

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer®...

3 months ago - Business Wire

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1781
CEO
Christophe Weber
Employees
47,495
Stock Exchange
NYSE
Ticker Symbol
TAK
Full Company Profile

Financial Performance

In 2019, TAK's revenue was 3.29 trillion, an increase of 56.93% compared to the previous year's 2.10 trillion. Earnings were 44.24 billion, a decrease of -67.28%.

Financial numbers in millions JPY.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 22.92, which is an increase of 35.86% from the latest price.

Price Target
$22.92
(35.86% upside)
Analyst Consensus: Buy